Literature DB >> 18511290

PHLiPPing the switch on Akt and protein kinase C signaling.

John Brognard1, Alexandra C Newton.   

Abstract

The Ser/Thr-specific phosphatase PHLPP [pleckstrin homology (PH) domain leucine-rich repeat protein phosphatase] provides 'the brakes' for Akt and protein kinase C (PKC) signaling. The two isoforms of this recently discovered family, PHLPP1 and PHLPP2, control the amplitude and duration of signaling of Akt and PKC by catalyzing the dephosphorylation of the hydrophobic phosphorylation motif, a C-terminal phosphorylation switch that controls these kinases. Aberrant regulation of either kinase accompanies many diseases, notably diabetes and cancer. By specifically dephosphorylating the hydrophobic motif, PHLPP controls the degree of agonist-evoked signaling by Akt and the cellular levels of PKC. This review focuses on the function of PHLPP1 and PHLPP2 in modulating signaling by Akt and PKC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18511290      PMCID: PMC2963565          DOI: 10.1016/j.tem.2008.04.001

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  63 in total

1.  Determination of a minimal region of loss of heterozygosity on chromosome 18q21.33 in osteosarcoma.

Authors:  Teresa L Johnson-Pais; Maggie J Nellissery; Donald G Ammerman; Dharmini Pathmanathan; Pardeep Bhatia; Carolyn L Buller; Robin J Leach; Marc F Hansen
Journal:  Int J Cancer       Date:  2003-06-10       Impact factor: 7.396

2.  Characterization of sporadic colon cancer by patterns of genomic instability.

Authors:  Ajay Goel; Christian N Arnold; Donna Niedzwiecki; Dong K Chang; Luigi Ricciardiello; John M Carethers; Jeannette M Dowell; Linda Wasserman; Carolyn Compton; Robert J Mayer; Monica M Bertagnolli; C Richard Boland
Journal:  Cancer Res       Date:  2003-04-01       Impact factor: 12.701

3.  Fine mapping of Wilms' tumors with 16q loss of heterozygosity localizes the putative tumor suppressor gene to a region of 6.7 megabases.

Authors:  Shawn D Safford; Dominique Goyeau; Alex J Freemerman; Rex Bentley; Mary Lou Everett; Paul E Grundy; Michael A Skinner
Journal:  Ann Surg Oncol       Date:  2003-03       Impact factor: 5.344

4.  Effects of rare earth compounds on growth and apoptosis of leukemic cell lines.

Authors:  Yucheng Dai; Jian Li; Jie Li; Li Yu; Ge Dai; Aiguo Hu; Liya Yuan; Zhu Wen
Journal:  In Vitro Cell Dev Biol Anim       Date:  2002 Jul-Aug       Impact factor: 2.416

Review 5.  Opposing roles of delta and epsilonPKC in cardiac ischemia and reperfusion: targeting the apoptotic machinery.

Authors:  Christopher L Murriel; Daria Mochly-Rosen
Journal:  Arch Biochem Biophys       Date:  2003-12-15       Impact factor: 4.013

6.  Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR.

Authors:  Hongbing Zhang; Gregor Cicchetti; Hiroaki Onda; Henry B Koon; Kirsten Asrican; Natalia Bajraszewski; Francisca Vazquez; Christopher L Carpenter; David J Kwiatkowski
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

7.  Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the Akt survival pathway.

Authors:  Yuichi Tanaka; M Veronica Gavrielides; Yasuhiro Mitsuuchi; Teruhiko Fujii; Marcelo G Kazanietz
Journal:  J Biol Chem       Date:  2003-06-24       Impact factor: 5.157

8.  TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver.

Authors:  Keyong Du; Stephan Herzig; Rohit N Kulkarni; Marc Montminy
Journal:  Science       Date:  2003-06-06       Impact factor: 47.728

9.  Insulin signaling through Akt/protein kinase B analyzed by small interfering RNA-mediated gene silencing.

Authors:  Zhen Y Jiang; Qiong L Zhou; Kerri A Coleman; My Chouinard; Queta Boese; Michael P Czech
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-13       Impact factor: 11.205

10.  Genome-wide analysis of allelic imbalance in prostate cancer using the Affymetrix 50K SNP mapping array.

Authors:  N Tørring; M Borre; K D Sørensen; C L Andersen; C Wiuf; T F Ørntoft
Journal:  Br J Cancer       Date:  2007-01-23       Impact factor: 7.640

View more
  98 in total

1.  Pleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP): a new player in cell signaling.

Authors:  Noel A Warfel; Alexandra C Newton
Journal:  J Biol Chem       Date:  2011-12-05       Impact factor: 5.157

2.  Suppression of survival signalling pathways by the phosphatase PHLPP.

Authors:  Audrey K O'Neill; Matthew J Niederst; Alexandra C Newton
Journal:  FEBS J       Date:  2012-03-16       Impact factor: 5.542

3.  Artificial Recruitment of UAF1-USP Complexes by a PHLPP1-E1 Chimeric Helicase Enhances Human Papillomavirus DNA Replication.

Authors:  David Gagnon; Michaël Lehoux; Jacques Archambault
Journal:  J Virol       Date:  2015-04-01       Impact factor: 5.103

Review 4.  The life and death of protein kinase C.

Authors:  Christine M Gould; Alexandra C Newton
Journal:  Curr Drug Targets       Date:  2008-08       Impact factor: 3.465

5.  Depletion of Pleckstrin homology domain leucine-rich repeat protein phosphatases 1 and 2 by Bcr-Abl promotes chronic myelogenous leukemia cell proliferation through continuous phosphorylation of Akt isoforms.

Authors:  Isao Hirano; Satoki Nakamura; Daisuke Yokota; Takaaki Ono; Kazuyuki Shigeno; Shinya Fujisawa; Kaori Shinjo; Kazunori Ohnishi
Journal:  J Biol Chem       Date:  2009-03-04       Impact factor: 5.157

Review 6.  Turning off AKT: PHLPP as a drug target.

Authors:  Alexandra C Newton; Lloyd C Trotman
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014       Impact factor: 13.820

7.  PH domain leucine-rich repeat protein phosphatase 2 (PHLPP2) regulates G-protein-coupled receptor kinase 5 (GRK5)-induced cardiac hypertrophy in vitro.

Authors:  Szu-Tsen Yeh; Cristina M Zambrano; Walter J Koch; Nicole H Purcell
Journal:  J Biol Chem       Date:  2018-04-08       Impact factor: 5.157

8.  PHLPP1 mediates melanoma metastasis suppression through repressing AKT2 activation.

Authors:  Yanlin Yu; Meng Dai; Andrew Lu; Ellen Yu; Glenn Merlino
Journal:  Oncogene       Date:  2018-02-02       Impact factor: 9.867

9.  Darpp-32 and its truncated variant t-Darpp have antagonistic effects on breast cancer cell growth and herceptin resistance.

Authors:  Long Gu; Sarah Waliany; Susan E Kane
Journal:  PLoS One       Date:  2009-07-13       Impact factor: 3.240

10.  Discovery of small molecule inhibitors of the PH domain leucine-rich repeat protein phosphatase (PHLPP) by chemical and virtual screening.

Authors:  Emma Sierecki; William Sinko; J Andrew McCammon; Alexandra C Newton
Journal:  J Med Chem       Date:  2010-10-14       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.